Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, United States

Survival: 17.6 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Los Angeles, CA
Hospital: University of Southern California Norris Comprehensive Cancer Center
Journal: Link
Date: 8/2013

This phase 3 study involved advanced castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A had 496 patients with a median age of 69 years. There were 498 patients in group B with a median age of 69 years.

Patients in group A were treated with the chemotherapy agent docetaxel.

Patients in group B were treated with docetaxel and the biologic therapy agent called atrasentan, which is an inhibitor of the endothelin receptor and may inhibit cancer metastases.

There were seven treatment-related deaths in group A due to respiratory failure, infection, heart failure, and skin toxicity.

There were three treatment-related deaths in group B due to bleeding and infection.

The median overall survival in groups A and B was 17.6 and 17.8 months, respectively.

This study was partially supported by Sanofi-Aventis and Abbott Laboratories.

Correspondence: Dr. David I Quinn; email:

E-mail to a Friend Email Physician More Information